Moleculin Signs Agreement with First Hospital for Annamycin Trials

Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, today announced that it has entered into an agreement to conduct its clinical trial to study Annamycin for the treatment of acute myeloid leukemia (AML) with the first of several hospitals desiring to be treatment centers.